[go: up one dir, main page]

BRPI0408555A - sistema de liberação controlada - Google Patents

sistema de liberação controlada

Info

Publication number
BRPI0408555A
BRPI0408555A BRPI0408555-8A BRPI0408555A BRPI0408555A BR PI0408555 A BRPI0408555 A BR PI0408555A BR PI0408555 A BRPI0408555 A BR PI0408555A BR PI0408555 A BRPI0408555 A BR PI0408555A
Authority
BR
Brazil
Prior art keywords
controlled release
release system
saib
solvent
additional
Prior art date
Application number
BRPI0408555-8A
Other languages
English (en)
Inventor
Kristine Fraatz
Dirk Mertin
Iris Heep
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0408555A publication Critical patent/BRPI0408555A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"SISTEMA DE LIBERAçãO CONTROLADA". A presente invenção refere-se a um sistema para liberação controlada de substâncias medicinalmente ativas, as quais compreendem isobutirato de acetato de sacarose (SAIB) e um adicional co-solvente.
BRPI0408555-8A 2003-03-20 2004-03-06 sistema de liberação controlada BRPI0408555A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312346A DE10312346A1 (de) 2003-03-20 2003-03-20 Kontrolliertes Freisetzungssystem
PCT/EP2004/002318 WO2004082658A1 (de) 2003-03-20 2004-03-06 Kontrolliertes freisetzungssystem enthaltend saccharoseacetatisobutyrat

Publications (1)

Publication Number Publication Date
BRPI0408555A true BRPI0408555A (pt) 2006-03-21

Family

ID=32920993

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408555-8A BRPI0408555A (pt) 2003-03-20 2004-03-06 sistema de liberação controlada

Country Status (18)

Country Link
US (1) US8231903B2 (pt)
EP (1) EP1608335B1 (pt)
JP (1) JP4863867B2 (pt)
AR (1) AR043423A1 (pt)
AT (1) ATE380017T1 (pt)
AU (1) AU2004222646B2 (pt)
BR (1) BRPI0408555A (pt)
CA (1) CA2519351C (pt)
CL (1) CL2004000566A1 (pt)
DE (2) DE10312346A1 (pt)
ES (1) ES2297396T3 (pt)
GT (1) GT200400045A (pt)
MX (1) MXPA05009910A (pt)
NO (1) NO20054776L (pt)
NZ (1) NZ542477A (pt)
PE (1) PE20041024A1 (pt)
TW (1) TW200505488A (pt)
WO (1) WO2004082658A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
HUE032040T2 (en) * 2004-09-17 2017-09-28 Durect Corp Saib-containing (sucrose acetate-isobutyrate) sustained-release local anesthetic composition
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
HUE030789T2 (en) * 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
EA018090B1 (ru) * 2008-05-28 2013-05-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Биохимической Физики Им. Н.М. Эмануэля Российской Академии Наук (Ибхф Ран) Средство для повышения октанового числа бензинового автомобильного топлива
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102764257B (zh) * 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种马来酸氟吡汀缓释片剂
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN103550150B (zh) * 2013-10-30 2016-06-08 北京中农华威制药有限公司 改进的含二甲基硅油的注射剂
CN103520099A (zh) * 2013-10-30 2014-01-22 王玉万 含有效成份为沃尼妙林的长效注射剂
CN103520168A (zh) * 2013-10-30 2014-01-22 游锡火 含延胡索酸泰妙菌素的复方注射剂
CN103550148A (zh) * 2013-10-30 2014-02-05 游锡火 延胡索酸泰妙菌素长效注射剂制备方法
CN103520098A (zh) * 2013-10-30 2014-01-22 王玉万 恩诺沙星兽用长效注射剂的制备方法
CN103536531A (zh) * 2013-10-30 2014-01-29 王玉万 甲磺酸达氟沙星长效注射剂制备方法
CN103550149A (zh) * 2013-10-30 2014-02-05 游锡火 含抗寄生虫药物长效注射剂的制备技术
CN103520167A (zh) * 2013-10-30 2014-01-22 游锡火 含硫酸头孢喹诺和甲磺酸达氟沙星的长效注射剂
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
AU2019260015C1 (en) 2018-04-25 2024-11-21 Elanco Animal Health Gmbh Process for the hydrolysis of quinolone carboxylic esters
WO2021028479A1 (en) 2019-08-14 2021-02-18 Vetoquinol S.A. Compositions comprising tigolaner for controlling parasites
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) * 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (pt) * 1985-09-18 1990-05-05 Pfizer
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE69524398T2 (de) * 1994-04-08 2002-07-18 Atrix Laboratories, Inc. Flüssige mittel zur wirkstoffabgabe
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
HU228036B1 (en) * 1996-02-23 2012-08-28 Bayer Animal Health Gmbh Optionally substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4,3,0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives, process producing them and medicaments thereof
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
RU2271196C2 (ru) * 1999-06-04 2006-03-10 Элзэ Копэрейшн Имплантируемая композиция (варианты) и способ ее приготовления
CN1399550A (zh) * 1999-08-03 2003-02-26 Awd药品股份有限两合公司 氟吡氨酯在减轻猫或犬退行性关节病相关性疼痛中的应用
AU2001259111B2 (en) * 2000-04-19 2005-12-08 Durect Corporation Sustained release formulations comprising growth hormone
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
US20050031650A1 (en) * 2002-08-26 2005-02-10 Ethypharm Composition with gelling properties for the sustained delivery of bioactive substances
DE10242088A1 (de) * 2002-09-11 2004-03-25 Bayer Ag Kontrolliertes Freisetzungssystem, welches Saccharoseacetatisobutyrat enthält

Also Published As

Publication number Publication date
JP4863867B2 (ja) 2012-01-25
EP1608335B1 (de) 2007-12-05
TW200505488A (en) 2005-02-16
GT200400045A (es) 2004-10-21
MXPA05009910A (es) 2005-11-04
CA2519351C (en) 2012-02-07
CA2519351A1 (en) 2004-09-30
US20060034926A1 (en) 2006-02-16
EP1608335A1 (de) 2005-12-28
ATE380017T1 (de) 2007-12-15
AR043423A1 (es) 2005-07-27
ES2297396T3 (es) 2008-05-01
US20090246277A9 (en) 2009-10-01
JP2006520346A (ja) 2006-09-07
DE10312346A1 (de) 2004-09-30
WO2004082658A1 (de) 2004-09-30
DE502004005652D1 (de) 2008-01-17
NZ542477A (en) 2009-02-28
NO20054776L (no) 2005-10-17
CL2004000566A1 (es) 2005-02-04
US8231903B2 (en) 2012-07-31
PE20041024A1 (es) 2005-01-27
AU2004222646A1 (en) 2004-09-30
AU2004222646B2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
BRPI0408555A (pt) sistema de liberação controlada
WO2006084164A3 (en) Gastric retention and controlled release delivery system
TW200735771A (en) Pesticide delivery system
WO2007124465A3 (en) Stable emulsion formulations
WO2007016093A3 (en) Peroxide removal from drug delivery vehicle
WO2002094210A3 (de) Kosmetische mittel
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
YU40701A (sh) Piperidini kao modulatori ccr5
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
IS6511A (is) Lyfjaefnablöndur sem innihalda sykurfitusýru estera til að stýra losun á virkum innihaldsefnum
WO2004022029A3 (en) Branched alcohol-based personal care compositions
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
ATE286736T1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
BRPI0620229A8 (pt) formulação
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
BR0314838A (pt) Sistema de liberação controlada, e, processo para preparar comprimidos de liberação controlada de temozolomida
MX2007013327A (es) Formulaciones de liberacion prolongada.
EA201000585A1 (ru) Многочастичная матричная система, содержащая галантамин
BRPI0518426A2 (pt) composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
ZA200809206B (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
UY28190A1 (es) Sistema de liberación controlada
WO2004032898A3 (de) Kontrolliertes freisetzungssystem, welches saccharoseacetatisobutyrat enthählt

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

Free format text: TRANSFERIDO DE: BAYER HEALTHCARE AG

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/44, 31/4709, 9/00, 47/06, 47/10, 47/26, 31/44, 31/4709, 9/00, 47/06, 47/10, 47/26

Ipc: A61K 31/44 (2011.01), A61K 31/4709 (2011.01), A61K

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]